Get the Stockscreener App
0.00
100.00%
-13.60
Pieris Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
See More
Previous Close:
$13.60
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$17.96M
Revenue:
$40.93M
Net Income/Loss:
$-23.82M
P/E Ratio:
0.00
EPS:
-18.71
Net Cash Flow:
$-37.87M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$22.32
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
Name
Pieris Pharmaceuticals Inc
Sector
Industry
Phone
857-246-8998
Address
225 FRANKLIN STREET, BOSTON, MA
Compare PIRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PIRS
Pieris Pharmaceuticals Inc
|
0.00 | 17.96M | 40.93M | -23.82M | -37.87M | -18.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.32 | 118.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.10 | 74.34B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
643.20 | 38.83B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.91 | 32.36B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.27 | 29.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Pieris Pharmaceuticals Inc Stock (PIRS) Latest News
TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor - ACCESS Newswire
Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease By Investing.com - Investing.com South Africa
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com - Defense World
Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada
Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com - Defense World
Twelve option delistings on December 23rd - TipRanks
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada
Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com
Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report
Pieris Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Julian Adams to its Board of Directors - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Claude Knopf as Senior Vice President and Chief Business Officer - Marketscreener.com
After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals
Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - The Manila Times
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent - The Bakersfield Californian
Palvella Therapeutics Announces Closing of Merger with - GlobeNewswire
Palvella Therapeutics Secures $79M Funding, Completes Merger with Strong Cash Position Through 2027 - StockTitan
Pieris Pharmaceuticals Announces Merger and Share Increase - TipRanks
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MyChesCo
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - The Eastern Progress Online
(PIRS) On The My Stocks Page - Stock Traders Daily
Pieris Pharmaceuticals announces board changes and merger update By Investing.com - Investing.com Nigeria
Pieris Pharmaceuticals announces board changes and merger update - Investing.com
(PIRS) Trading Report - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, ACNB, PIRS, OBDE on Behalf of Shareholders - The Malaysian Reserve
Comparing Evelo Biosciences (NASDAQ:EVLO) and Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
How To Trade (PIRS) - Stock Traders Daily
Lynx1 Capital Management LP Adjusts Stake in Pieris Pharmaceuticals Inc - GuruFocus.com
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
Pieris Pharmaceuticals Inc Stock (PIRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pieris Pharmaceuticals Inc Stock (PIRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GERAGHTY JAMES A | Director |
Aug 07 '24 |
Buy |
1.00 |
1 |
1 |
1 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 12 '24 |
Buy |
15.88 |
3,000 |
47,647 |
129,574 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 09 '24 |
Buy |
14.89 |
3,000 |
44,679 |
127,331 |
1.08%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):